Introduction {#S5}
============

Interstitial lung disease (ILD) can be defined by the presence of diffuse parenchymal opacities on chest imaging and restrictive physiology not attributable to cardiac disease, infection, exposures or other identifiable cause.^[@R1]^ ILD is frequently associated with connective tissue disease (CTD), its frequency varying with the specific type of CTD, and the diagnostic criteria used.^[@R2]^ For example, ILD was present in 58% of 36 rheumatoid arthritis (RA) patients with early joint disease but clinically significant in only 14% of patients.^[@R3]^ ILD was present in 65% of cases of newly diagnosed dermatomyositis and polymyositis,^[@R4]^ and had a major impact on morbidity and mortality.^[@R5]^ ILD may affect up to 70% of patient with systemic sclerosis (SSc) where it represents the most common cause of death.^[@R6]^ It may be less frequent in systemic lupus erythematosus (SLE) but is associated with increase in mortality.^[@R7]^ Interestingly, ILD may be the first manifestation of CTD in 15% of the cases and may precede the diagnosis of CTD by up to two years.^[@R8]^ Therefore, screening for CTD is not only recommended whenever systemic complaints suggestive of CTD are present, but it may also be considered with each new diagnosis of ILD. This is particularly true in case of rapidly progressive or chronic ILD, where polymyositis (PM), dermatomyositis DM), SLE, and RA are among the possible differential diagnoses.^[@R9]^

Since diagnostic manifestations of CTD are not always present at the time of diagnosis of ILD,^[@R10]^ the clinician may wonder whether the ILD is the first^[@R11]^ or isolated manifestation of autoimmune-featured ILD^[@R12]^ or lung-dominant form of CTD.^[@R13]^ Laboratory data may include antinuclear antibody (ANA), autoantibodies to extractable nuclear antigens (ENA), rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (CCP), anti-Jo-1 antibody, creatinine kinase, aldolase, erythrocyte sedimentation rate and C-reactive protein.^[@R10]^ However, the benefit of routinely measuring autoimmune biomarkers to evaluate ILD remains controversial.^[@R14]^ Although it is recommended to assess for biochemical tests and/or serology markers in order not to overlook an underlying CTD,^[@R15]^ there are limited data about the influence of such findings on the occurrence, severity and prognosis of ILD^[@R16],\ [@R17]^. Therefore, the goal of this study was to determine if positive autoimmune biomarkers were associated with ILD and how their presence would influence outcome, using a case-control study design in a large tertiary referral center. Our hypothesis was that patients with positive autoimmune biomarkers had increased odds of developing ILD, even in the absence of overt CTD. Identification of autoimmune biomarkers strongly associated with ILD could identify a subgroup of patients that deserve specific focus of research on diagnosis, management and outcome.

Methods {#S6}
=======

a. Study design {#S7}
---------------

This was a case-control study, using the database of the first five years of the ILD clinic Mayo Clinic Rochester registry. All adult patients, including women and racial/ethnic minorities, were included, some with a diagnosis of ILD, some to rule out ILD and some with nonspecific pulmonary issues, between September 26, 2001 and September 26, 2006. We only included patients who had given permission for their medical records to be used for research.

b. Definition of ILD {#S8}
--------------------

ILD was diagnosed by a pulmonologist based on a combination of clinical history, physical examination, chest imaging, pulmonary function testing, and pathology findings during the initial and/or subsequent visits. ILD was defined, as previously described,^[@R18]^ by the presence of diffuse parenchymal opacities on chest imaging (chest radiographs or computerized tomography) and restrictive physiology, not attributable to congestive heart failure, infection (pneumonia), cancer or other non-ILD causes. We included patients with patterns of ILD associated with CTD:^[@R19],\ [@R20],\ [@R21]^ usual interstitial pneumonia (UIP), suspected (computerized tomography findings only) or confirmed (biopsy), nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), lymphoid interstitial pneumonia (LIP) and pulmonary fibrosis not-otherwise specified or unclassifiable (from isolated strand of fibrosis to undetermined fibrosis after extensive evaluation sometimes including lung biopsy). Cases of diffuse alveolar damage were excluded. After a careful history and physical examination, focusing on comorbidities, medication use, environmental exposures, and family history, and using a standardized approach, we excluded patients with ILDs of other known causes or other distinct types of ILD: hypersensitivity pneumonitis, drug toxicity, smoking-related ILD, radiation pneumonitis, sarcoidosis, eosinophilic pneumonias, vasculitis, and rare forms of ILD (*e.g*., lymphangioleiomyomatosis, pulmonary alveolar proteinosis). All individual medical records were then reviewed through June 25, 2013.

c. Definition of biomarkers {#S9}
---------------------------

Predictor variables sought included ANA, ENA (including anti-SSA/Ro, anti-SSB/La, anti-RNP, anti-Sm, anti-Jo1, and anti-Scl70), RF, CCP and aldolase measured at any time. Quantitative determination of ANA (negative \<1 U) and ENA (negative \<25 U) were measured by enzyme immunoassay, RF (negative \<15 U) by particle-enhanced immunoturbidimetric assay, CCP (negative \<20 U) by binding to the wells of a commercial microtiter plate coated with synthetic CCP (Quanta Lite CCP3 IgG ELISA, INOVA Diagnostics) and aldolase from the rate at which NADH is oxidized to NAD measured photometrically by a decrease in absorbance (negative \<7.4 U).

Controls were defined as patients who were seen in the ILD clinic, but did not have ILD.

d. Definition of CTD {#S10}
--------------------

CTD, a strong potential confounding variable, was diagnosed by a rheumatologist, according to established criteria,^[@R10]^ based on the combination of clinical history, physical examination, and laboratory and radiologic findings during the initial and/or subsequent visits in the rheumatology clinic of the same institution, at any time. For ILD, the date of first symptoms and/or abnormal chest imaging were collected based on clinician evaluation as reported in the chart (i.e. persistent dyspnea, or cough or evidence or 'rales' or 'crackles') or first abnormal chest radiographic finding, whichever came first. For CTD, the date of first symptoms and/or abnormal laboratory finding was collected based on clinician evaluation as reported in the chart. CTD included rheumatoid arthritis, polymyositis/dermatomyositis including anti-synthetase syndrome, systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, Sjögren syndrome, and undifferentiated connective tissue diseases. Undifferentiated CTD was defined as a condition characterized by the presence of signs and symptoms suggestive of a systemic autoimmune disease that did not satisfy the classic criteria for defined CTD.^[@R22]^ Patients seen in the ILD clinic during the study period but with no diagnosis of ILD or CTD, served as controls (non-cases from the same source). Potential effect modifiers included age, gender, race, and smoking status. Date of death and last follow up was ascertained until June 25, 2013 when it was censored.

e. Sample size {#S11}
--------------

Sample size for this unmatched case-control study was estimated at 516 in each group, with a probability of type I error of 0.05, a power of 0.8, expected proportion in control cases of 0.05 and a relative risk of 2 (2 sided test).^[@R23]^ For a sample size of 774 the power was estimated at 0.93 with the same parameters, otherwise.

f. Bias {#S12}
-------

In order to limit sampling biases, all patients seen at the same clinic, during the study period, were considered for the study and only patients who had declined to have their charts reviewed for research purpose were excluded (n=316). To limit measurement biases, variables were collected through electronic records available since 1996. Study data were collected and managed using JMP® Pro (version 9.0.1, SAS Institute Inc., Cary, NC).

g. Statistical methods {#S13}
----------------------

Demographics are expressed as median with interquartile range (IQR) for continuous variables and as number with percentage for categorical variables. Comparisons between groups used Wilcoxon's test and odd ratio with confidence interval and Chi-square test as appropriate. The association of demographics and autoimmune biomarkers with ILD was assessed using logistic regression. Given the known association of CTD with ILD, these analyses were performed separately for patients with and without CTD. Among patients with ILD, survival following onset of ILD symptoms was assessed using left truncated Kaplan--Meier and Cox proportional-hazards regression analyses. Since, for some patients, the diagnosis of CTD occurred after the onset of ILD symptoms, this variable was included in the Cox model using a binary time dependent covariate and supplemental analyses were performed which excluded patients whose CTD diagnosis occurred following their initial ILD clinic visit. Analyses were performed using SAS software (SAS version 9, SAS Institute Inc, Cary, NC) (ACH and DRS). Sensitivity analyses evaluated separately patients coming from the USA only and those from Minnesota only. A subgroup of ILD without clear evidence of CTD was independently reviewed by a pulmonologist (SK) and a rheumatologist (TGO).

This study was conducted in accordance with the amended Declaration of Helsinki and approved by the Mayo Clinic (13-001307) institutional review board.

Results {#S14}
=======

During the 5-year recruitment period, a total of 5326 patients were available for review. After excluding 316 patients who declined to have their medical records reviewed for research, and 1437 ILD patients with other known causes or distinct types of ILDs, 3573 cases were included for further study ([Figure 1](#F1){ref-type="fig"}). There were 1256 (13%) cases with ILD alone, and 2317 (65%) without ILD. We further identified 930 (26%) cases with ILD alone, 326 (9%) cases with combined ILD and CTD (CTD-ILD), 124 (3%) cases with CTD alone, and 2193 (61%) cases with no ILD or CTD ([Figure 1](#F1){ref-type="fig"}). Rheumatology consultation occurred in 121 (34%) cases with ILD alone, 302 (93%) cases with combined ILD and CTD, 1 (100%) case with CTD alone (diagnosis established by Rheumatology elsewhere prior to the visit to the ILD clinic) and 10 (16%) cases with no ILD or CTD. Among ILD cases, 326 (26%) had CTD and among non-ILD cases, 124 (5%) had CTD (OR 6.20, 95% CI 4.97--7.73) ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Most cases of CTD were associated with ILD (72%). Overall, patients with ILD (69 years, 60--76) were older than patients without ILD (65 years, 54--74). Patients with CTD-ILD (59 years, 50--68) were younger than those without CTD (72 years, 65--77). Although the percentage of current smokers was lower in patients with ILD vs. no ILD (2.3% vs. 9.2%), the percentage of previous smokers was higher (54.6% vs. 48.6%). Male gender, race, older age, smoking status and presence of CTD were all independent predictors of ILD.

The most frequent tests ordered ANA (47% of all cases), RF (34%), and ENA (30%). ILD was more frequently observed in 326 (72%) cases with CTD and in 261 (56%) cases with positive test but no evidence of CTD, than in 669 (25%) cases with no CTD (p\<0.0001). Overall, positive testing for ANA, ENA, RF and aldolase were independent variables associated with ILD ([Table 3a and 3b](#T3){ref-type="table"}).

Among patients with ILD but no overt CTD, positive serologies were seen in different subtypes of ILD, mainly with UIP and unclassifiable pulmonary fibrosis and less often with organizing pneumonia or NSIP ([Table 4](#T4){ref-type="table"}). A restrictive pattern appeared more pronounced in case of UIP and NSIP than with OP or unclassifiable pulmonary fibrosis. On high resolution computed tomography, honeycombing and traction bronchiectasis were more frequent with a UIP pattern than with unclassifiable pulmonary fibrosis.

In the presence of CTD, a positive ANA alone (OR 2.34, 95% CI 1.42--3.85) or aldolase alone (OR 2.79, 95% CI 1.07--7.28), were each predictors of ILD. In the absence of CTD, both positive ANA (OR 1.52, 95% CI 1.17--1.96) and RF (OR 2.06, 95% CI 1.46--2.91) were associated with an increased likelihood of ILD. These findings were not affected by restricting the study to the US population or to the residents of Minnesota alone. After adjustment for age, gender, race, smoking history and connective tissue disease, ANA remained an independent risk factor for ILD (OR 1.70, 95% CI 1.33--2.17).

Patients with CTD-ILD had better survival than patients with ILD alone and patients with both ILD and biomarkers (p=0.001) ([Figure 2](#F2){ref-type="fig"}). Median survival was 20 years, 10 years and 10.5 years for those with CTD-ILD, ILD with positive biomarkers only and ILD alone, respectively.

Discussion {#S15}
==========

In this case-control study of patients seen in a tertiary referral ILD center, we found significant associations between the presence of positive biomarkers, including ANA, RF and aldolase, and ILD. We also found that patients with ILD alone (with or without the presence of positive biomarkers) had worse survival than those patients with CTD-ILD. The higher percentage of UIP in those with ILD without CTD (56%), including ILD with positive biomarkers only (52%), and ILD alone (58%), compared to CTD-ILD (9%) could explain this difference in survival since a UIP pattern is associated with worse survival compared to other types^[@R24]^. The greater frequency of pulmonary fibrosis not otherwise specified in CTD-ILD (74%) compared with ILD alone (34%) may reflect clinical practice of not pursuing pathological diagnosis in presence of CTD, since the distinction between a fibrotic NSIP and a UIP pattern in the context of CTD is contended to not influence outcome, with the possible exception of rheumatoid arthritis where a UIP pattern may be associated with a worse outcome than fibrotic NSIP^[@R25]^. We found that some cases of ILD were associated with positive biomarkers but without overt CTD and postulate that they may represent an occult form of CTD.^[@R26]^ Isolated NSIP, which has been associated with undifferentiated CTD^[@R27],\ [@R28]^, was rarely present, that is 6 (1%) out of 169 cases of ILD with positive ANA but no overt CTD or 14 (5%) of 261 cases of ILD with at least one positive autoimmune biomarker. This may reflect the definition used by the clinicians to define undifferentiated CTD-associated ILD as any ILD with at least one auto-antibody and at least one extra-thoracic feature,^[@R2],\ [@R22]^ thus leaving those ILD with a positive serology but no apparent extra-thoracic feature of auto-immune disease in a separate category. Nevertheless, and although there is a known correlation with older age and positive ANA or RF,^[@R29]^ as well as an increased incidence of ILD with age,^[@R30]^ especially idiopathic pulmonary fibrosis,^[@R31]^ the presence of both positive biomarkers and ILD could, in the absence of overt CTD, suggest the possibility of isolated pulmonary form of CTD.

In presence of ILD, the clinical relevance of a positive biomarker alone, without evidence of CTD, is unknown. In a subgroup analysis, we carefully reviewed 261 cases of ILD with no evidence of CTD but with at least one positive biomarker. The proportion of observed agreement by an independent pulmonologist was 98% for the presence of ILD and, by a reviewing rheumatologist not directly involved in their care, 92% for the absence of CTD, while suggesting 20 cases of possible undiagnosed CTD. Thus, a positive biomarker alone could indicate an increased risk for ILD either associated with subclinical CTD or reflecting an immunologic process associated with idiopathic interstitial pneumonia^[@R32]^. However, the lack of survival benefit in this subgroup of patients when compared to isolated forms of ILD seems to indicate that, contrary to overt CTD, the natural course or response to immunosuppressive therapy may be similar to idiopathic interstitial pneumonias. Whether or not this specific group of patients requires specific treatment usually reserved for ILD associated CTD, or showed response to such treatment if given, is unknown and was not directly addressed in this study.

The field of ILD studied was restricted to UIP, NSIP, OP, LIP and other unclassifiable pulmonary fibrosis, that have all been associated with CTD.^[@R8]^ Other types of idiopathic interstitial pneumonias such as desquamative interstitial pneumonia and respiratory bronchiolitis interstitial lung disease, which are strongly associated with smoking^[@R33]^, were excluded. Acute interstitial pneumonia^[@R34]^ occurs in a very unique setting and was also excluded. We believe these would encompass the type of ILD one would expect even with occult CTD, without sacrificing too much sensitivity or specificity. To limit selection biases, the presence of ILD and CTD were assessed separately and based on the opinion of the clinician who had evaluated the patient. However, cases of CTD may have had ILD but not been referred to the ILD clinic and cases of ILD may have developed CTD later without follow up or recognition by us.

The first limitation is the retrospective design of this study, as attested by an overall relatively low proportion of patients tested for ANA (47%) and even less for other biomarkers (i.e. aldolase), which may represent a sampling bias. Overall, ANA testing was performed in 71% of all ILD, which is consistent with 76% of at least one antibody assayed in ILD patients by others^[@R35]^. Testing was most frequently performed in presence of CTD, with or without ILD (87 versus 80%). Testing was also performed in the absence of CTD, and more often in patients with than without ILD (66 versus 31%).

The second limitation is the choice of the index date as the appointment date in the ILD clinic of a tertiary referral center, and therefore the uncertainty as to the exact inception date of ILD, as some cases were simply referred for a second opinion regarding diagnosis, etiology and prognosis of ILD previously diagnosed and evaluated elsewhere. The same holds true for the diagnosis of CTD. To address these two concerns, the outcome was evaluated from the first symptom of ILD reported by the clinician in the initial evaluation and not from the date of appointment in the ILD clinic. Although subject to limitation (recollection bias), this is probably less subjective than using the date of visit to the clinic^[@R36],\ [@R37]^.

As a third limitation, the selection of the population from a tertiary referral center and the predominantly white race may limit the generalizability of this study to other institutions, populations and other ethnic groups.

In summary {#S16}
----------

This study shows that the presence of positive autoimmune biomarkers, such as ANA, RF, and aldolase was associated with increased odds of ILD, even in the absence of overt CTD. After adjustment for age, gender, race, smoking history and CTD, ANA remained an independent risk factor for ILD. In case of ILD most commonly encountered with CTD, the presence of CTD was associated with a better outcome than either ILD with positive antibodies or ILD alone. Whether or not the group of ILD with positive autoimmune biomarker but not extra-thoracic manifestation of CTD represents a different category of patients warrants further study.
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ANA

:   antinuclear antibodies

CCP

:   anti-cyclic citrullinated peptide antibodies

CI

:   confidence interval

CTD

:   connective tissue disease

CTD-ILD

:   interstitial lung disease associated with connective tissue disease

ENA

:   autoantibodies to extractable nuclear antigens

ILD

:   interstitial lung disease

LIP

:   lymphoid interstitial pneumonia

MCTD

:   mixed connective tissue disease

NSIP

:   nonspecific interstitial pneumonia

OP

:   organizing pneumonia

OR

:   odds ratio

PF-NOS

:   pulmonary fibrosis non-otherwise specified or unclassifiable

PM/DM

:   polymyositis/dermatomyositis including anti-Jo1 antibody disease

RA

:   rheumatoid arthritis

RF

:   rheumatoid factor

SLE

:   systemic lupus erythematosus

SSc

:   systemic sclerosis

UCTD

:   undifferentiated connective tissue disease

UIP

:   usual interstitial pneumonia

![Flow diagram: number of cases per category. The group 'Declined' corresponds to those who did not consent. 'Excluded' represents other forms of ILD (ILD, interstitial lung disease; CTD, connective tissue disease)](nihms662446f1){#F1}

![Survival plot of interstitial lung disease cases from the time of first symptoms according to presence or absence of CTD at the time of initial ILD clinic visit, and positive or negative biomarkers; Log-Rank test, p=0.0001 (ILD, interstitial lung disease; CTD, connective tissue disease; solid line, ILD with CTD; dotted line, ILD with positive biomarkers only; half-dashed line, ILD with negative biomarker)](nihms662446f2){#F2}

###### 

Types and distribution of interstitial lung disease and connective tissue disease[†](#TFN1){ref-type="table-fn"}

  --------------------------------------------------------------------------------------
  Characteristics   ILD\        No ILD\                                     
                    (n=1256)    (n=2317)                                    
  ----------------- ----------- ---------- --------- ---------- ----------- ------------
  CTD (n=450)       29 (9%)     35 (11%)   19 (6%)   2 (\<1%)   241 (74%)   124 (5%)

    RA              8 (28%)     6 (17%)    3 (16%)   0 (0%)     64 (27%)    62 (50%)

    PM/DM           4 (14%)     7 (20%)    5 (26%)   0 (0%)     27 (11%)    6 (5%)

    SSc             3 (10%)     6 (17%)    2 (11%)   0 (0%)     59 (24%)    13 (10%)

    SLE             0 (0%)      2 (6%)     0 (0%)    1 (50%)    13 (5%)     6 (5%)

    MCTD            7 (24%)     7 (20%)    2 (11%)   1 (50%)    48 (20%)    14 (11%)

    Sjögren         2 (7%)      3 (9%)     1 (5%)    0 (0%)     9 (4%)      11 (9%)

    UCTD            5 (17%)     4 (11%)    6 (31%)   0 (0%)     21 (9%)     12 (10%)

  No CTD (n=3123)   522 (56%)   39 (4%)    51 (6%)   2 (\<1%)   316 (34%)   2193 (95%)
  --------------------------------------------------------------------------------------

ILD, interstitial lung disease; CTD, connective tissue disease; UIP, usual interstitial pneumonia; NSIP, nonspecific interstitial pneumonia; OP, organizing pneumonia; LIP, lymphoid interstitial pneumonia; PF-NOS, pulmonary fibrosis non-otherwise specified or unclassifiable; RA, rheumatoid arthritis; PM/DM, poly-/dermatomyositis; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; MCTD, mixed connective tissue disease; UCTD, undifferentiated connective tissue disease

###### 

characteristics of predictors of ILD[†](#TFN2){ref-type="table-fn"}

  Characteristics                               ILD           No ILD        OR (95% CI)[\*](#TFN4){ref-type="table-fn"}   P value[\*\*](#TFN5){ref-type="table-fn"}
  --------------------------------------------- ------------- ------------- --------------------------------------------- -------------------------------------------
  CTD                                                                                                                     
    Overall                                     n=326         n=124                                                       
    Age (year)[§](#TFN3){ref-type="table-fn"}   59 (50--68)   63 (53--70)   0.94 (0.87--1.02)                             ns
    Female                                      223 (68)      93 (75)       0.72 (0.45--1.15)                             ns
    White                                       262 (80)      111 (90)      0.48 (0.25--0.91)                             0.024
    Smoking                                                                                                               0.002
      Never                                     176 (54)      55 (44)       Ref.                                          
      Previous                                  141 (43)      55 (44)       0.80 (0.52--1.24)                             
      Current                                   9 (3)         14 (11)       0.20 (0.08--0.49)                             
  No CTD                                                                                                                  
    Overall                                     n=930         n=2193                                                      
    Age (year)[§](#TFN3){ref-type="table-fn"}   72 (65--77)   66 (54--74)   1.24 (1.20--1.28)                             \<0.001
    Female                                      368 (40)      1077 (49)     0.68 (0.58--0.79)                             \<0.001
    White                                       763 (82)      1857 (85)     0.83 (0.67--1.01)                             0.067
    Smoking                                                                                                               \<0.001
      Never                                     365 (39)      921 (42)      Ref.                                          
      Previous                                  545 (59)      1072 (49)     1.28 (1.09--1.50)                             
      Current                                   20 (2)        200 (9)       0.25 (0.16--0.41)                             

ILD, interstitial lung disease; CTD, connective tissue disease; OR, odds ratio; CI, confidence interval;

Values are median (IQR) or number (percentage);

odds ratios represents 5 year increase in age;

P-values are from logistic regression; ns, not significant

  a: Values of biomarkers[†](#TFN6){ref-type="table-fn"}                                                        
  -------------------------------------------------------- ----- --------------------- ----- ------------------ ----------
  CTD                                                                                                           
    ANA (\<1U)                                             258   3.05 (1.075--8.325)   89    1.4 (0.5--5.2)     0.0011
    ENA (\<25 U)                                           267   10.3 (3.4--148.5)     66    6.1 (2.5--130.6)   ns
    RF (\<15 U)                                            233   0 (0--125)            91    28 (0--190)        0.0375
    CCP (\<20 U)                                           100   0 (0--72)             44    2.5 (0--100)       ns
    Aldolase (\<7.4 U)                                     120   7.8 (5.5--16.05)      23    5.7 (4.2--8.1)     0.0098
  No CTD                                                                                                        
    ANA (\<1U)                                             602   0.6 (0.3--1.1)        656   0.5 (0.3--0.8)     \<0.0001
    ENA (\<25 U)                                           416   3.7 (2.2--6.675)      320   3.4 (2.025--5.9)   ns
    RF (\<15 U)                                            466   0 (0--16)             417   0 (0--0)           \<0.0001
    CCP (\<20 U)                                           171   0 (0--0)              97    0 (0--0)           ns
    Aldolase (\<7.4 U)                                     49    5.1 (4.35--7.05)      111   5.3 (4.4--6.9)     ns

  b: Positive biomarkers as predictors of ILD[†](#TFN10){ref-type="table-fn"}                                                          
  ----------------------------------------------------------------------------- ----- ---------- ----- ---------- -------------------- ----------
  CTD                                                                                                                                  
    ANA                                                                         285   227 (80)   99    62 (63)    2.34 (1.42--3.85)    0.0007
    ENA                                                                         270   116 (43)   66    25 (38)    1.24 (0.71--2.15)    ns
    RF                                                                          235   111 (47)   91    58 (64)    0.51 (0.31--0.84)    0.0075
    CCP                                                                         100   37 (37)    44    21 (48)    0.64 (0.31--1.32)    ns
    Aldolase                                                                    120   66 (55)    23    7 (30)     2.79 (1.07--7.28)    0.0309
  No CTD                                                                                                                               
    ANA                                                                         611   169 (28)   681   137 (20)   1.52 (1.17--1.96)    0.002
    ENA                                                                         421   23 (6)     321   14 (4)     1.26 (0.64--2.50)    ns
    RF                                                                          467   120 (26)   418   60 (14)    2.06 (1.46--2.91)    \<0.0001
    CCP                                                                         171   4 (2)      97    1 (1)      2.30 (0.25--20.87)   ns
    Aldolase                                                                    49    12 (24)    111   26 (23)    1.06 (0.48--2.33)    ns

ILD, interstitial lung disease, CTD, connective tissue disease; ANA, antinuclear antibodies; ENA: extractable nuclear antigens; RF, rheumatoid factor; CCP; anti-cyclic citrullinated peptide antibodies; U, units representing cutoff values; IQR, interquartile range;

Number of patients with biomarker value available;

P-value from Wilcoxon Test; ns, not significant

(\*when available; IQR, interquartile range)

OR, odds ratio; CI, confidence interval;

Number of patients with the given biomarker assessed;

P-value from logistic regression; ns, not significant

###### 

Subtypes of ILD with positive serologies in the absence of overt CTD[†](#TFN13){ref-type="table-fn"}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                      ILD\          P value[\*\*](#TFN16){ref-type="table-fn"}                                             
                                                       (n=261)                                                                                              
  ---------------------------------------------- ----- ------------- -------------------------------------------- ------------- ------------- ------------- ----------
  Demographics                                                                                                                                              

    Age (year)[§](#TFN14){ref-type="table-fn"}   261   71 (65--77)   68 (55--74)                                  68 (64--78)   27 (27--27)   73 (66--78)   

    Female                                       121   57 (42)       9 (64)                                       7 (47)        1 (100)       47 (49)       ns

    White                                        213   107 (79)      10 (71)                                      12 (80)       0 (0)         84 (88)       ns

  Biomarkers, n (%)                                                                                                                                         

    ANA                                          253   81 (63)       6 (43)                                       12 (80)       1 (100)       69 (73)       ns

    ENA                                          190   13 (13)       1 (8)                                        2 (22)        0 (0)         7 (10)        ns

    RF                                           219   63 (54)       10 (91)                                      6 (60)        1 (100)       40 (50)       ns

    CCP                                          65    2 (6)         0 (0)                                        0 (0)         0 (0)         2 (91)        ns

    Aldolase                                     29    6 (43)        3 (60)                                       0 (0)         0 (0)         3 (30)        ns

  PFT[§](#TFN14){ref-type="table-fn"}                                                                                                                       

    TLC (%)                                      229   67 (59--75)   61 (49--66)                                  73 (59--92)   \-            72 (62--80)   0.002

    FVC (%)                                      254   65 (53--76)   52 (42--60)                                  74 (56--95)   97            69 (51--79)   0.0231

    FEV1 (%)                                     254   71 (60--80)   54 (44--67)                                  75 (58--80)   85            71 (59--82)   0.0446

    FEV1/FVC                                     254   84 (81--89)   82 (76--95)                                  80 (73--82)   76            82 (76--88)   0.0021

    DLCO (%)                                     238   47 (34--57)   37 (27--52)                                  47 (22--68)   94            50 (39--59)   ns

    DLCO adj (%)                                 174   47 (35--55)   36 (29--58)                                  49 (33--60)   92            49 (39--56)   ns

  HRCT                                                                                                                                                      

    Honeycombing                                 196   102 (89)      2 (18)                                       3 (43)        0 (0)         39 (62)       \<0.0001

    Bronchiectasis                               195   101 (93)      9 (82)                                       5 (63)        0 (0)         55 (82)       0.0277

    Reticularity                                 240   127 (100)     12 (92)                                      11 (85)       0 (0)         85 (98)       0.0011

    GGO                                          115   31 (70)       9 (82)                                       7 (88)        1 (100)       46 (90)       ns
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

ILD, interstitial lung disease, CTD, connective tissue disease; ANA, antinuclear antibodies; ENA: extractable nuclear antigens; RF, rheumatoid factor; CCP; anti-cyclic citrullinated peptide antibodies;

Values are median (IQR);

Number and percentage of patients with the given characteristic assessed;

p value from Chi-square or Wilcoxon as appropriate; ns, not significant, PFT, pulmonary function test; TLC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; DLCO, diffusing capacity for carbon monoxide; DLCO adj, diffusing capacity for carbone monoxide adjusted for hemoglobin; HRCT, high resolution computed tomography; GGO, ground glass opacities
